Hangzhou, Zhejiang, China Tigermed is the famous Corporate Investor, which was founded in 2004. The venture was found in Asia in China. The leading representative office of defined Corporate Investor is situated in the Hangzhou.
The usual cause for the fund is to invest in rounds with 3 partakers. Despite the Tigermed, startups are often financed by UCLA Ventures, Tech Coast Angels, Taikang Life Insurance. The meaningful sponsors for the fund in investment in the same round are Yingke Capital, Taiyu Capital, TF Capital. In the next rounds fund is usually obtained by Reimagined Ventures, National Institutes of Health.
Among the most popular portfolio startups of the fund, we may highlight Neural Analytics, CMAB BioPharm. The fund has no exact preference in some founders of portfolio startups. For fund there is a match between the country of its foundation and the country of its the most frequent investments - China. Among the most successful fund investment fields, there are Software, Electronics. Moreover, a startup needs to be at the age of 2-3 years to get the investment from the fund.
This organization was formed by Xiaoping Ye.
Deals in the range of 10 - 50 millions dollars are the general things for fund. The high activity for fund was in 2018. The fund is constantly included in less than 2 investment rounds annually. Speaking about the real fund results, this Corporate Investor is 13 percentage points more often commits exit comparing to other organizations.
Related Funds
| Fund Name | Location |
| Brience | California, San Francisco, United States |
| CWB Capital | - |
| Jiaguang Zichan | China, Hangzhou, Zhejiang |
| Predata | New York, New York, United States |
| Soham Vencaps | - |
| SpaceVest | Great Falls, United States, Virginia |
| The Strand Partners | Boca Raton, Florida, United States |
| Toyo Kanetsu Corporate Venture Investment Partnership | Japan, Tokyo |
| Westwood Holdings Group | Dallas, Texas, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Bivision | $15M | 26 Jul 2024 | Shanghai, Shanghai, China | ||
Hipower | 13 Oct 2022 | Guangzhou, Guangdong, China | |||
LTZ Therapeutics | $17M | 07 Apr 2022 | San Francisco, California, United States | ||
BioInno | 21 Dec 2021 | Beijing, Beijing, China | |||
Jisi Yingda | 15 Nov 2021 | Shanghai, Shanghai, China | |||
| $78M | 09 Mar 2021 | Shangcheng District, Zhejiang, China | |||
Hinova Pharma | $154M | 06 Oct 2020 | Qingyang District, Sichuan, China | ||
Adlai Nortye | $100M | 31 Aug 2020 | Shangcheng District, Zhejiang, China | ||
Asieris Pharmaceuticals | $44M | 28 Jun 2020 | Shanghai, China |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Bivision | $15M | 26 Jul 2024 | Shanghai, Shanghai, China | ||
Hipower | 13 Oct 2022 | Guangzhou, Guangdong, China | |||
LTZ Therapeutics | $17M | 07 Apr 2022 | San Francisco, California, United States | ||
BioInno | 21 Dec 2021 | Beijing, Beijing, China | |||
Jisi Yingda | 15 Nov 2021 | Shanghai, Shanghai, China | |||
| $78M | 09 Mar 2021 | Shangcheng District, Zhejiang, China | |||
Hinova Pharma | $154M | 06 Oct 2020 | Qingyang District, Sichuan, China | ||
Adlai Nortye | $100M | 31 Aug 2020 | Shangcheng District, Zhejiang, China | ||
Asieris Pharmaceuticals | $44M | 28 Jun 2020 | Shanghai, China |
